SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 11 | November 2024 - Peer Reviewed Journal

A REVIEW OF ANALYSIS ON MPOX (MONKEY POX VIRUS) A GLOBAL PANDEMIC

Mr. Nikhil Mabrukar[1], Ms. Aishwarya Kamble[2] , Dr. Vijaysinha Sable[3]
[1]Author, [2]Guide , [3]Principal

ABSTRACT

Mpox, previously known as monkeypox, is a zoonotic viral disease caused by the monkeypox virus, which is a member of the Ortho poxvirus genus.

Although historically endemic to Central and West Africa, recent outbreaks have highlighted its potential to spread more widely.

Mpox is characterized by symptoms similar to smallpox, including fever, rash, and lymphadenopathy, with a progression from flu-like symptoms to a distinctive rash that evolves from macules to pustules.

Transmission occurs through direct contact with infectious bodily fluids, lesions, or contaminated materials, and can also be zoonotic, involving animals such as rodents.

Recent global outbreaks have prompted increased surveillance, public health responses, and vaccination efforts. Research continues to focus on improving diagnostic methods, understanding the virus's epidemiology, and developing effective treatments and vaccines.

Given its potential for widespread dissemination, continued vigilance and preparedness are essential to managing and mitigating future outbreaks. [1]

KEYWORDS: *MPOX , Vaccination , DROC , Orthopoxviruses , Chickenpox , Clade I , Clade II .*

INTRODUCTION

Although mpox is uncommon among children in the United States, pediatrics cases have been identified during the 2022 global mpox outbreak. Vaccines and antiviral drugs established for other Ortho poxviruses are now extensively used to prevent and treat mpox in both children and adults in the United States. Although the scientific literature on mpox in children and adolescents is limited, previous case reports can provide important information about the clinical characteristics and potential sequel of untreated clade II mpox in these age groups. [2]

In this review, we summaries the epidemiology and clinical aspects of mpox in children and adolescents, In May 2022, an unprecedented global outbreak of mpox(previously known as monkey pox) was recognized. Since then, over 80,000 cases have been identified in nonendemic nations, including over 29,000 in the United States. Although the current global outbreak has predominantly affected adults, over 500 laboratory confirmed cases in children and adolescents have been reported worldwide, with many more children and adolescents being exposed to the mpoxvirus (MPXV). [1]

There are two well-defined MPXV clades with distinct clinical characteristics: clade I (previously known as the Congo Basin Clade) and clade II (formerly known as the West African Clade). The vast majority of published research, including mostpediatric case reports, covers infection with clade I MPXV, which has been linked to greater severity and higher-class fatality rate than clade II . Because of their relevance to the current outbreak, this review focuses on outbreak and pediatric case reports of clade II MPOXV infection. As the outbreak progress, pediatricians and other health care practitioners who care for children and adolescents should be prepared to recognise, diagnose, and treat mpox and it's consequences, as well as contribute to preventive efforts, [2]

Epidemiology

The Ortho poxviruses MPXV is endemic to West and Central Africa and is capable of infecting both people and animals. Despite the fact that the virus was first identified in caged monkeys and given the moniker "monkey pox," the most likely reservoir species is small ground rats. Close skin-to-skin contact or mucosal contact with lesions are the most prevalent ways that MPXV is transferred. Respiratory secretions and transplacenta transmission are thought to occur less frequently. The most typical way for humans to become infected is by contact with other sick people or animals; fomite-facilitated transmission through towels, linens, or other household items can also happen. the MPXV format requires 3 to 17 days to incubate. Depending on how the condition was acquired, there can be differences in its severity and clinical presentation the Congo reported the first known human case of mpox. instances total—five involving children—were documented in three West African countries in 1970 and 1971. In the 1970s

SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 11 | November 2024 - Peer Reviewed Journal

and 1980s, more cases of mpox were documented in Central Africa once it was discovered to be a zoonosis that can infect humans. The majority of cases were in youngsters, and most were sporadic or happened in small clusters after a common animal exposure. Initially, it was believed that there was not much room for prolonged person-to-person transmissions or recently, during a 2003 outbreak of clade II MPXV in the United States, children and adolescents accounted for 26% of confirmed or probable cases sickness was linked to contact with pet prairie dogs co-housed with imported small animals from Africa.[3]

Cross-protection against mpox is provided by the smallpox immunisation. Adults
are becoming more vulnerable to MPXV as decades have passed since the standard smallpox immunisation program ceased in 1972; the median age of cases that have been reported has risen from 4 years in the 1970s to 21 years in the 2010s. Whether age-related physiological changes in MPXV sensitivity exist independently of vaccination status is unknown. Unlike previous outbreaks, the ongoing 2022 outbreak in the United States has resulted in 0.3% of cases to date being caused by children and teenagers under the age of the comparatively low number of MPXV infections among children in 2022 is probably due to a significant change in transmission, in addition to the absence of immunity among the majority of adults: mpox is now mostly (though not exclusively) disseminated through close, intimate human-to-human contact. It has spread especially among gay, bisexual, and other males who have sex with men in their social networks as a result, it is critical that pediatricians stay vigilant for the risk of mpox when caring for adolescent or young adult males who have sex with male partners, even though mpox can afflict people of various ages, gender identities, and sexual orient [4]

Mpox, previously known as monkeypox, is a zoonotic viral disease caused by the monkeypox virus, which is a member of the Ortho poxvirus genus.
Although historically endemic to Central and West Africa, recent outbreaks have highlighted its potential to spread more widely.
Mpox is characterized by symptoms similar to smallpox, including fever, rash, and lymphadenopathy, with a progression from flu-like symptoms to a distinctive rash that evolves from macules to pustules.

Transmission occurs through direct contact with infectious bodily fluids, lesions, or contaminated materials, and can also be zoonotic, involving animals such as rodents.

Recent global outbreaks have prompted increased surveillance, public health responses, and vaccination efforts. Research continues to focus on improving diagnostic methods, understanding the virus's epidemiology, and developing effective treatments and vaccines. Given its potential for widespread dissemination, continued vigilance and preparedness are essential to managing and mitigating future outbreaks.[2]

Clinical Trials
The hallmark of mpox is a rash with well-circumscribed, deep-seated, solid or rubbery lesions that, in later stages, are frequently umbilicated. Macular, popular, vesicular, and pustular phases of the rash are followed by scabbing over and desquamation (Fig 1). The rash may appear in different parts of the body at different frequently hurt or itch. During the disease, fever, chills, myalgia's, or malaise can strike at any point. Additionally, lymphadenopathy is frequently seen.

Mpox photographs. Clinical images show an early vesicle (1A), an umbilicated pustule (1B), an ulcerated lesion (1C), and a generalised pustular rash (1D). 1A, 1B, and 1C images are credited to the UK Health Security Agency. 1D image credit: NHS England's High Consequence Infectious Diseases Network. The severity, complications, and case fatality ratios (CFR) of mpox may differ in children and adults. Other Ortho poxviruses, such as variola and vaccinia, have been shown to put children at risk for serious consequences.1Historical accounts of the severity of clade I mpox in children and adolescents indicate increased severity in children [5]

linked to greater severity and a higher case fatality rate than clade II.Because of their relevance to the current outbreak, this review focusses on outbreak and pediatric case reports of clade II MPXV infection. As the outbreak progresses, pediatricians and other healthcare practitioners who care for children and adolescents should be prepared to recognize, diagnose, and treat mpox and its consequences, as well as contribute to preventative efforts. [2]

SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 11 | November 2024 - Peer Reviewed Journal

Figure No. 1



Congo from 1980 to 1985 found that children under 8 years old, especially those under 4 years old, had a higher CFR of up to 15%. However, a further analysis revealed that the mortality rate attributable to clade I mpox in the Democratic Republic of Congo is lower than previously reported due to possible underreporting of cases and misattribution of death from mpox. Finally, of the 92 potential instances included in the latter study, three deaths were linked to mpox, and all three occurred in patients under the age of three. [5]

Clinical Descriptions of Clade II Mpox Before 2022 Outbreak

Here are few detailed accounts of clade II mpox, including its consequences and severity in children and teenagers. For this review of clade II mpox prior to the current outbreak, we searched multiple databases for articles in English that included a pediatric age-related term (e.g., "NICU," "preschool," or "teenager") and a term related to mpox or mpox vaccines or therapeutics (e.g., "monkey pox," "MPXV," "JYNNEOS," or "tecovirimat"). We summarised papers presenting individual case level data for patients under 18 years old with confirmed or probable mpox.

Cases were limited to those caused by clade II MPXV, which was identified through molecular genotyping or inferred from location in West Africa. We included cases from outbreaks in Nigeria, Sierra Leone, Ivory Coast, and Liberia from 1970 to 1979, as well as the 2003 outbreak in the United States, a 2017 outbreak in Nigeria, and one additional 2019 case from Sierra Leone. These findings are complemented with previously unreported case data from the 2003 US outbreak provided by the US. Centres for Disease Control and Prevention (CDC). [5]

SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 11 | November 2024 - Peer Reviewed Journal

Table No.1

	1970-1990	1991-1999	2000-2009	2010-2018
Democratic Republic of Congo (former Zaire)	386 (confirmed) (27) + 2–5 (28, 29)	511 (28, 30)	Not fully enumerable (8, 11, 24)	Not fully enumerable (18, 31–34)
Central African Republic	6 (confirmed) (35)	N/A*	4 (19)	At least 68 (at least 29 confirmed) (19, 34, 36–38)
Cameroon	2 (confirmed) (27, 39)	4 (1 confirmed) (28, 29, 40, 41)	N/A*	16 (1 confirmed) (34)
Nigeria	10 (3 confirmed) (42–44)	N/A*	N/A*	244 (101 confirmed) (34)
Ivory Coast	2 (confirmed) (43, 45)	N/A*	N/A*	N/A*
Liberia	4 (confirmed) (42, 46)	N/A*	N/A*	2 (confirmed) (19)
Sierra Leone	1 (confirmed) (42, 46)	N/A*	N/A*	At least 2 (2 confirmed) (19, 40, 47)
Gabon	1–10 (one confirmed) (28, 29, 40, 48)	N/A*	N/A*	N/A*
USA	N/A*	N/A*	47 (37 confirmed, 10 probable) (49, 50)	N/A*
Republic of Congo	N/A*	N/A*	12 (3 confirmed, 8 probable) (51, 52)	98 (9 confirmed) (53, 54)
South Sudan	N/A*	N/A*	49 (10 confirmed, 9 probable) (55)	N/A*

*Confirmation status mentioned between brackets if known. * No information available*

Table No.1 Confirms Cases According To Country

Every patient acquired a rash. Of the 22 patients, 17 (77%) had more clinical information available. The rash was described as papular, vesicular, pustular, or umbilicated, which is consistent with descriptions of clade II MPXV infections in adults Lesions were most commonly recorded on the trunk, palms or soles, arms or hands, back, and legs or feet. All cases in whom rash distribution was characterised had a generalised rash. Fever, chills, or sweats were present in 12 (71%) of 17 cases, lymphadenopathy in 8 (47%) (with cervical lymphadenopathy being the most prevalent), sore throat in 7 (41%), headache in 7 (41%), and myalgias in 4 (24%). As postexposure prophylaxis (PEP), a 12-year-old child who had mpox had recently gotten the live vaccine known as Dryvax. Seven days following the vaccination, symptoms appeared. He didn't need to stay at a hospital. It's unclear how the immunisation helped this patient's symptoms lessen. Neither vaccinations nor MPXV-directed treatments were given to anyone else [5].

Clinical Description During 2022

In 2022, cases of mpox in children and adolescents have been reported from several different nations. Compared to earlier clade II mpox epidemics, the severity and rate of complications appear to be lower, which could be due to early diagnosis, easy access to healthcare, the availability of antiviral medication, or other factors. An overview of pediatric cases in the US in 2022 included 83 cases: Conjunctivitis, discomfort, and secondary skin infections were among the problems that occurred; 22% of patients received antiviral therapy, 11% were hospitalised, none needed intensive care unit care, and no deaths were reported. An investigation on instances in Spain, with ages ranging from 7 months to 17 years, found that none of the patients got antiviral therapy, one developed a small secondary skin infection, and none necessitated hospitalisation.

In 2022, a number of clinical case reports of newborns with clade II mpox were reported. An MPXV and adenovirus-infected newborn was reported to have a generalised rash and respiratory failure in a UK publication. According to a Florida report, a baby under two months old was admitted to the hospital due to possible secondary skin infections and mpox lesions around the eyes. The baby was treated with tecovirimat, intravenous vaccine (VIGIV), and preventive ocular trifluridine, and eventually made a good recovery. Finally, a 7-month-old baby in Spain recovered totally without therapy after a brief episode of illness.

Adult cases of mpox in the current outbreak have been characterised by relatively localised disease, most commonly involving the genitals, though a variety of dermatologic and other symptoms have been documented. In the present outbreak.

SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 11 | November 2024 - Peer Reviewed Journal

Reported complications of mpox in adults include proctitis, urethritis, phimosis, balanitis, secondary bacterial skin infections, conjunctivitis, and other visual problems, as well as encephalomyelitis. Children and adolescents who contract mpox during the current outbreak may be at risk for these problems. Sexually active teenagers with anogenital lesions are especially susceptible to anal or genitourinary problems. [6]

Diagnosis

When considering mpox in children and adolescents, other conditions that cause rashes are likely to be considered, such as varicella (chickenpox), herpes zoster (shingles), hand, foot, and mouth disease, scabies, molluscum, contagiosum, impetigo, measles, herpes simplex virus, syphilis, allergic skin rashes, drug eruptions, and a variety of congenital infections in neonates. Unlike varicella lesions, which exhibit regional pleomorphism, mpox lesions in a single location of the body are usually at the same stage of evolution. Although the mpox rash takes around 2 to 4 weeks to develop, many other rash disorders, such as varicella, progress much faster. He specific characteristics of lesions, slow progression, and painful or pruritic nature can help distinguish the mpox rash from other systemic rashes. Other sexually transmitted infections (STIs) to consider in sexually active adolescents with genital lesions include syphilis, chancroid, herpes simplex virus, and lymphogranuloma venereum. [2]

MPXV testing should be undertaken if epidemiologic criteria are met or if clinical characteristics provide a strong suspicion. The ideal method for testing Ortho poxviruses is polymerase chain reaction (PCR), which is currently accessible in public health and certain private laboratories. Sample collection should include thorough swabbing, although unroofing or aspirating the lesion is neither necessary nor advised. Testing the crust is also an option. Single laboratory test results should be interpreted with caution in patients with a low risk of mpox.32 Serologic testing for MPXV may be considered as an adjuvant in patients who have not been immunised against Ortho poxviruses if there is a risk of false positive testing or if testing the rash is impossible.

MPOXV Treatment

As of this writing, the US Food and Drug Administration (FDA) has not approved any drugs to treat mpox, and there is no clinical trial data to guide therapeutic decisions. Investigational drugs can be considered to treat children and adolescents with severe illness (e.g., sepsis, encephalitis); those with involvement of anatomic areas that may result in serious sequelae, such as scarring or strictures; and those who may be at increased risk for severe illness, such as children under the age of one year, those with immunocompromising conditions, and those with eczema or any other condition that causes a break in the skin. [6]

Tecovirimat is an antiviral medicine that was originally intended to fight smallpox.
It is now used as the first-line treatment for mpox in the United States under an Expanded Access Investigational New Drug protocol. Tecovirimat appears to be well tolerated in adults, while its efficacy is unknown; outcome data from the present outbreak are being gathered, including data from randomised controlled trials. Tecovirimat has been administered to infants, children, and adolescents in at least 18 cases in the United States, including 8 children under the age of five, and a newborn as young as ten days old in the United Kingdom. Dosing for infants and children under 13 kg has not yet been determined, and the difficulty of attaining precise dosing and adequate absorption with enteral tecovirimat must be balanced against the risk of nephrotoxicity from intravenous tecovirimat. Other therapies may be considered as adjuncts or alternatives to tecovirimat after consulting with doctors and public health authorities. VIGIV is licensed for the treatment of vaccinia virus vaccine problems and has already been used for this purpose; it has also been administered to small infants during the present outbreak with no documented adverse events. Other antiviral drugs, notably cidofovir and its prodrug, brincidofovir, have shown in vitro effectiveness against Ortho poxviruses, but their usage is limited by possible renal and hepatic damage. The examples shown in Table 1 illustrate clade II mpox problems that have been reported in pediatric patients. In children with mpox, treatment teams should be on the lookout for indications of encephalitis. To reduce the danger of a secondary skin infection, lesions should be cleaned and covered. It's also important to make sure kids don't contact their eyes after touching lesions or pick at them. MPXV infections in the eyes have the potential to be blinding and leave a lasting corneal scar. Given the potential of autoinoculation, topical trifluridine can be used in conjunction with ophthalmology to treat mpox's ocular symptoms as well as a preventive measure for lesions on the eyelid or near the eye.

Prevention

Pediatric healthcare professionals are crucial in the fight against mpox. Importantly, adolescents with a history of sexual activity, especially men who engage in sexual activity with other men, may benefit from more extensive counselling for multiple sclerosis (mpox), including behavioral preventive techniques, identification of mpox symptoms, and vaccination as preexposure prophylaxis (PrEP).Adolescents and young adults who are determined to be at increased risk for mpox, such as gay, bisexual, or other MSM, transgender, or nonbinary people with more than one sexual partner in the last six months, or those diagnosed with a STI in the last six months, as well as those who anticipate experiencing the above risks, should be offered mpox PrEP where minor consent laws allow or with parental consent [8]

SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 11 | November 2024 - Peer Reviewed Journal

According to current US guidelines, individuals who have mpox should stay away from other people during the whole period of their illness, from the moment symptoms start to appear until lesions have healed, scabs have come off, and a new layer of skin has grown. Individuals who have mpox should refrain from touching, tending to others, including kids, or sharing a bed with others who do not have the virus. The present outbreak has also shown that there may be significant surface contamination in the home, indicating the potential for transmission through termites. Homes where mpox patients have resided should be cleaned from the surfaces, and clothes and other linens worn by mpox patients should be washed. [8]

REFERENCE

1. *World Health Organization. 2022 monkeypox outbreak: global trends. Available at: https://worldhealthorg.shinyapps.io/mpx_global/. Accessed November 1, 2022*
2. *Mbala PK, Huggins JW, Riu-Rovira T, et al. Maternal and fetal outcomes among pregnant women with human monkeypox infection in the Democratic Republic of Congo. J Infect Dis. 2017;216(7): [824–828]*
3. *Mpox in Children and Adolescents: Epidemiology, Clinical Features, Diagnosis, and Management Amy M. Beeson, MD; Julia Haston, MD, MSc; David W. McCormick, MD, MPH; Mary Reynolds, PhD; Kevin Chatham-Stephens, MD, MPH; Andrea M. McCollum, PhD; Shana Godfred-Cato*
4. *Reynolds MG, Yorita KL, Kuehnert MJ, et al. Clinical manifestations of human monkeypox influenced by route of infection. J Infect Dis. 2006;194(6): [773–780]*
5. *Jezek Z, Grab B, Paluku KM, Szczeniowski MV. Human monkeypox: disease pattern, incidence and attack rates in a rural area of northern Zaire. Trop Geogr Med. 1988;40(2):–6.Jezek Z, Szczeniowski M, Paluku KM, Mutombo M. Human monkeypox: clinical features of 282 patients. J Infect Dis. 1987;156(2):[293–298]*
6. *Breman JG, Kalisa-Ruti, Steniowski MV, Zanotto E, Gromyko AI, Arita I. Human monkeypox, 1970-79. Bull World Health Organ. 1980;58(2):[165–182]*
7. *Nolen LD, Osadebe L, Katomba J, et al. Extended human-to-human transmission during a monkeypox outbreak in the Democratic Republic of the Congo. Emerg Infect Dis. 2016;22(6): [1014–1021]*
8. *Hennessee I, Shelus V, McArdle CE, et al; California Department of Public Health Monkeypox Pediatric Working Group; CDC Monkeypox Pediatric Working Group. Epidemiologic and clinical features of children and adolescents aged <18 years with monkeypox – United States, May 17-September 24, 2022. MMWR Morb Mortal Wkly Rep. 2022;71[44]*